Inflammation and cancer: Role of nuclear factor-kappaB activation

Cancer Science

Volumn 99, Issue 5, 2008, Pages 836-842

  Maeda, Shin ^a,b   Omata, Masao ^b  

^a INSTITUTE FOR ADULT DISEASES   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BAY 11; DEHYDROXYMETHYLEPOXYQUINOMICIN; DOXORUBICIN; GENISTEIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PARTHENOLIDE; PROTEASOME INHIBITOR; STEROID; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CANCER INVASION; CANCER PREVENTION; CANCER THERAPY; CARCINOGENESIS; CELL INFILTRATION; CHRONIC GASTRITIS; CHRONIC INFLAMMATION; COLITIS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; GENE MUTATION; HELICOBACTER PYLORI; HUMAN; INFLAMMATION; INNATE IMMUNITY; LIVER CANCER; LIVER CARCINOGENESIS; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; STOMACH CARCINOGENESIS; TRANSCRIPTION REGULATION; TUMOR VASCULARIZATION; ANIMAL; BIOLOGICAL MODEL; CELL TRANSFORMATION; IMMUNOLOGY; LIVER TUMOR; METABOLISM; NEOPLASM; STOMACH TUMOR;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; INFLAMMATION; LIVER NEOPLASMS; MODELS, BIOLOGICAL; NEOPLASMS; NF-KAPPA B; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 43649109029     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00763.x     Document Type: Review

References (63)

1. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology (Williston Park) 2002; 16 (217-26): 29; discussion 30-2.
2. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
3. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991; 325: 1132-6.
4. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004; 127: S35-50.
5. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.
6. Yoshida H, Shiratori Y, Moriyama M et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 1999; 131: 174-81.
7. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002; 3: 221-7.
8. Hoffmann A, Baltimore D. Circuitry of nuclear factor kappaB signaling. Immunol Rev 2006; 210: 171-86.
9. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002; 109 (Suppl): S81-96.
10. Li Z-W, Chu W, Hu Y et al. The IKKβ subunit of IκB kinase (IKK) is essential for NF-κB activation and prevention of apoptosis. J Exp Med 1999; 189: 1839-45.
11. Lee EG, Boone DL, Chai S et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000; 289: 2350-4.
12. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003; 424: 801-5.
13. Pomerantz JL, Baltimore D. Two pathways to NF-kappaB. Mol Cell 2002; 10: 693-5.
14. Claudio E, Brown K, Park S, Wang H, Siebenlist U. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol 2002; 3: 958-65.
15. Coope HJ, Atkinson PG, Huhse B et al. CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J 2002; 21: 5375-85.
16. Dejardin E, Droin NM, Delhase M et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002; 17: 525-35.
17. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280-8.
18. Kabrun N, Enrietto PJ. The Rel family of proteins in oncogenesis and differentiation. Semin Cancer Biol 1994; 5: 103-12.
19. Bartsch H, Nair J. Oxidative stress and lipid peroxidation-derived DNA-lesions in inflammation driven carcinogenesis. Cancer Detect Prev 2004; 28: 385-91.
20. Yamanishi Y, Boyle DL, Rosengren S, Green DR, Zvaifler NJ, Firestein GS. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 2002; 99: 10.025-30.
21. Tada M, Komatsu Y, Kawabe T et al. Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: Clinical utility for diagnosis of pancreatic tumor. Am J Gastroenterol 2002; 97: 2263-70.
22. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
23. Zumkeller W, Schofield PN. Growth factors, cytokines and soluble forms of receptor molecules in cancer patients. Anticancer Res 1995; 15: 343-8.
24. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004; 4: 937-47.
25. Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha. a potential target for the therapy of solid tumours. Lancet Oncol 2003; 4: 565-73.
26. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999; 19: 5785-99.
27. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-6.
28. Bian X, McAllister-Lucas LM, Shao F et al. NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J Biol Chem 2001; 276: 48.921-9.
29. Ivanov VN, Ronai Z. p38 protects human melanoma cells from UV-induced apoptosis through down-regulation of NF-kappaB activity and Fas expression. Oncogene 2000; 19: 3003-12.
30. Kiriakidis S, Andreakos E, Monaco C, Foxwell B, Feldmann M, Paleolog E. VEGF expression in human macrophages is NF-kappaB-dependent. studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaBalpha and a kinase-defective form of the IkappaB kinase 2. J Cell Sci 2003; 116: 665-74.
31. Strieter RM, Polverini PJ, Arenberg DA et al. Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J Leukoc Biol 1995; 57: 752-62.
32. Yoshida S, Ono M, Shono T et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997; 17: 4015-23.
33. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-74.
34. Luo JL, Tan W, Ricono JM et al. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 2007; 446: 690-4.
35. Keats JJ, Fonseca R, Chesi M et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12: 131-44.
36. Demicco EG, Kavanagh KT, Romieu-Mourez R et al. RelB/p52 NF-kappaB complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor IkappaB-alpha expression and promote carcinogenesis of the mammary gland. Mol Cell Biol 2005; 25: 10.136-47.
37. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66: 605-12.
38. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004; 6: 447-58.
39. Varney ML, Johansson SL, Singh RK. Tumour-associated macrophage infiltration, neovascularization and aggressiveness in malignant melanoma: Role of monocyte chemotactic protein-1 and vascular endothelial growth factor-A. Melanoma Res 2005; 15: 417-25.
40. Mizukami Y, Jo WS, Duerr EM et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med 2005; 11: 992-7.
41. Ulloa L, Messmer D. High-mobility group box 1 (HMGB1) protein: Friend and foe. Cytokine Growth Factor Rev 2006; 17: 189-201.
42. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005; 121: 977-90.
43. Maeda S, Hikiba Y, Shibata W et al. Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochem Biophys Res Commun 2007; 360: 394-400.
44. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. J Clin Invest 2007; 117: 60-9.
45. Bodger K, Crabtree JE. Helicobacter pylori and gastric inflammation. Br Med Bull 1998; 54: 139-50.
46. Censini S, Lange C, Xiang Z et al. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci USA 1996; 93: 14.648-53.
47. Hirata Y, Ohmae T, Shibata W et al. MyD88 and TNF receptor-associated factor 6 are critical signal transducers in Helicobacter pylori -infected human epithelial cells. J Immunol 2006; 176: 3796-803.
48. Maeda S, Yoshida H, Ogura K et al. H. pylori activates NF-kappaB through a signaling pathway involving IkappaB kinases, NF-kappaB-inducing kinase, TRAF2, and TRAF6 in gastric cancer cells. Gastroenterology 2000; 119: 97-108.
49. Viala J, Chaput C, Boneca IG et al. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat Immunol 2004; 5: 1166-74.
50. Maeda S, Yoshida H, Ikenoue T et al. Structure of cag pathogenicity island in Japanese Helicobacter pylori isolates. Gut 1999; 44: 336-41.
51. Ogura K, Maeda S, Nakao M et al. Virulence factors of Helicobacter pylori responsible for gastric diseases in Mongolian gerbil. J Exp Med 2000; 192: 1601-10.
52. Yanai A, Maeda S, Shibata W et al. Activation of IkappaB kinase and NF-kappaB is essential for Helicobacter pylori-induced chronic gastritis in Mongolian gerbils. Infect Immun 2008; 76: 781-7.
53. Greten FR, Eckmann L, Greten TF et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285-96.
54. Becker C, Fantini MC, Schramm C et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004; 21: 491-501.
55. May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, Ghosh S. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 2000; 289: 1550-4.
56. Shibata W, Maeda S, Hikiba Y et al. Cutting edge: The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis. J Immunol 2007; 179: 2681-5.
57. Maeda S, Chang L, Li ZW, Luo JL, Leffert H, Karin M. IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha. Immunity 2003; 19: 725-37.
58. Tang G, Minemoto Y, Dibling B et al. Inhibition of JNK activation through NF-kappaB target genes. Nature 2001; 414: 313-17.
59. Sakurai T, Maeda S, Chang L, Karin M. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci USA 2006; 103: 10.544-51.
60. Fausto N. Liver regeneration. J Hepatol 2000; 32: 19-31.
61. Naugler WE, Sakurai T, Kim S et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317: 121-4.
62. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling. balancing life and death - a new approach to cancer therapy. J Clin Invest 2005; 115: 2625-32.
63. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5: 297-309.